Patent application number | Description | Published |
20120045348 | Integral Plus Proportional Dual Pump Switching System - A dual-pump fluid distribution system that includes a first pump having an inlet and an outlet, and configured to supply a first flow of fluid, and a second pump having an inlet and an outlet, and configured to supply a second flow of fluid. In an embodiment, a bypass flow valve with a four-way hydraulic bridge is configured to initiate the switch between single-pump mode and dual-pump mode based on fluid flow demand. The bypass flow valve is configured such that the position of the bypass flow valve member relative to the four-way hydraulic bridge operates a pump selector valve. In an embodiment, the pump selector valve has a valve member, a biasing element, and a pressure switching port, and is configured such that the position of the valve member determines whether the second flow of fluid is combined with the first flow of fluid. | 02-23-2012 |
20130042920 | Split Control Unit - A split control unit in a distributed flow unit includes a flow inlet configured to receive a fuel flow, a first manifold having flow lines to supply fuel to one or more primary nozzles, and a second manifold having flow lines to supply fuel to one or more secondary nozzles. In an embodiment, the second manifold is in fluid communication with the flow inlet. A metering valve has a first port in fluid communication with the flow inlet and with the second manifold. The metering valve is configured to supply a metered fuel flow to the first manifold. A flow passage is in fluid communication with, and runs between, a flow line of the first manifold and a flow line of the second manifold to allow for a continuous cooling flow in the second manifold when all of the one or more secondary nozzles are closed. | 02-21-2013 |
20130043331 | Staged Cooling Flow Nozzle Valve - A fuel split control arrangement is provided. The arrangement includes a staged cooling flow control valve and cooling check valve. The staged cooling flow control valve and cooling check valve is connected between the primary and secondary tips of a nozzle in a turbine engine. The staged cooling flow control valve and cooling check valve includes a valve member arrangement operable to prevent fuel flow from the secondary fuel supply manifold to the secondary tip and simultaneously allow fuel flow from the secondary fuel supply manifold to the primary tip such that the primary tip receives fuel flow from both the secondary fuel supply manifold and the primary fuel supply manifold. | 02-21-2013 |
20150020888 | Parallel Metering Pressure Regulation System for a Thermal Efficient Metering System - A fuel pressure regulation system is provided. The fuel pressure regulation system includes a supply arrangement for supplying an outlet flow. A primary metering circuit is provided, an inlet of which receives a first portion of the outlet flow of the supply arrangement, the primary metering circuit comprising a fuel metering valve and a primary pressure regulator. The primary pressure regulator is connected to an outlet of the fuel metering valve. The system also includes at least one secondary metering circuit. The primary pressure regulator is operably connected to the at least one secondary metering circuit to sense a pressure of the at least one secondary metering circuit. The system also includes a bypass regulator connected in parallel with the primary metering circuit and the least one secondary metering circuit such that an inlet of the bypass regulator receives a second portion of the outlet flow of the supply arrangement. | 01-22-2015 |
Patent application number | Description | Published |
20080241156 | Inhibitors of hepatitis C virus - The present invention relates to methods that employ peptides or peptide derivatives to inhibit hepatitis C virus infection. The present invention is based in part on the discovery that E2 envelope glycoprotein of hepatitis C virus has previously undescribed domains that are important for interactions with cellular or viral proteins that are necessary for early steps in HCV infection. The present invention provides peptides and methods of treatment and prophylaxis of diseases induced by hepatitis C virus and related viruses. | 10-02-2008 |
20090209464 | Flavivirus fusion inhibitors - The present invention relates to peptides and methods of inhibiting fusion between the virion envelope of Flaviviruses and membranes of the target cell, the process that delivers the viral genome into the cell cytoplasm. The invention provides for methods which employ peptides or peptide derivatives to inhibit Flavivirus:cell fusion. The present invention is based in part on the discovery that E1 envelope glycoprotein of hepaciviruses and E2 envelope glycoprotein of pestivirus have previously undescribed structures, truncated class II fusion proteins. The present invention provides peptides and methods of treatment and prophylaxis of diseases induced by Flaviviruses. | 08-20-2009 |
20090264362 | Influenza virus inhibiting peptides - The present invention provides a pharmaceutical composition for the treatment or prevention of an influenza infection. The composition comprises an isolated polypeptide including a sequence of at least 8 contiguous amino acid residues of the fusion initiation region (FIR) of an influenza hemagglutinin 2 protein or a peptide analog of the sequence. The FIR is a segment of the full length hemagglutinin 2 protein which is bounded by an amino-terminal region within the amino-terminal alpha-helix thereof and a carboxy terminus within the carboxy-terminal alpha-helix thereof, with a cysteine loop therebetween. The amino-terminal region of the FIR comprises a portion of the final 10 to 20 amino acid residues of the amino-terminal alpha-helix of the hemagglutinin 2 protein, and includes 3 or 4 hydrophobic amino acid residues, a positively-charged amino acid residue, a negatively-charged amino acid residue, and an aromatic amino acid residue. The carboxy terminus of the FIR is the carboxy terminus of the first peptide sequence of the hemagglutinin 2 protein beyond the amino terminal helix, which exhibits a positive Wimley-White interfacial hydrophobicity. | 10-22-2009 |
20100152109 | Influenza inhibiting compositions and methods - The present invention provides peptides, peptide analogs, peptide derivatives and pharmaceutical compositions useful for treating or preventing influenza infections or preventing the person-to-person transmission of an influenza infection. A peptide of the invention comprises an influenza virus-cell fusion inhibiting portion of the fusion initiation region (FIR) of a wild-type influenza hemagglutinin 2 protein or a variant thereof. In a preferred embodiment, a peptide of the invention consists of 8 to 40 consecutive amino acid residues a portion of a wild-type influenza hemagglutinin 2 protein or a variant thereof, the portion of the protein comprising the FIR of the protein and up to five amino acid residues on the amino-terminal and carboxy-terminal sides of the FIR. | 06-17-2010 |
20100261640 | SOLUBLE AND MEMBRANE ANCHORED FORMS OF LASSA VIRUS SUBUNIT PROTEINS - The invention discloses compositions comprising soluble and membrane-anchored forms of Lassa virus (LASV) glycoprotein 1 (GP1), glycoprotein 2 (GP2), the glycoprotein precursor (GPC), the nucleocapsid protein (NP), and the nucleic acids encoding these proteins. This invention further relates to diagnostic and preventative methods using these compositions. Preventative methods include preparation of vaccines, as well as factors (e.g. small molecules) that inhibit LASV infectivity. Further, the invention relates to diagnostic and therapeutic antibodies including neutralizing antibodies for the prevention and treatment of infection by LASV and other arenaviruses. | 10-14-2010 |
20110130328 | FLAVIVIRUS FUSION INHIBITORS - The present invention provides an isolated peptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:36, as well as derivatives thereof comprising various N-terminal and C-terminal chemical moieties, substituted analogs thereof, and fragments thereof. The peptides of the invention are useful for treating and preventing a Flavivirus invention. Pharmaceutical compositions comprising the peptides, and methods of treating or preventing Flavivirus infections, are also provided. | 06-02-2011 |
20120219576 | LASSA VIRUS-LIKE PARTICLES AND METHODS OF PRODUCTION THEREOF - The instant invention is directed to novel Lassa virus-like particle (VLP) compositions and methods of production thereof. The inventive VLPs comprise, for example, the Lassa virus (LASV) Z matrix protein, glycoproteins (GPs)-I and -2, and nucleoprotein (NP). A novel method for producing these VLPs comprises constructing multicistronic plasmids for the expression of VLP protein components from a single vector. One example is a tricistronic vector containing DNA sequences encoding the LASV Z, GPC and NP proteins. The VLPs provided by the present invention can be used for research, therapeutic and diagnostic purposes. | 08-30-2012 |
20120289458 | TREATMENT OF INFLUENZA VIRUS INFECTION - The present invention provides method for the treatment of an ongoing influenza infection by administering a polypeptide to a subject suffering from an influenza infection. The polypeptide consists of the fusion initiation region (FIR) of an influenza hemagglutinin 2 protein or an 8 to 40 amino acid residue portion thereof. In one embodiment, the polypeptide consists of SEQ ID NO: 4 or an 8 to 40 contiguous amino acid residue portion thereof. The present invention also provides a method of interfering with fusion of an influenza virus envelope with a host cell membrane by contacting the host cell with the FIR polypeptide. | 11-15-2012 |
20130005648 | PEPTIDE COMPOSITIONS AND METHODS FOR INHIBITING HERPESVIRUS INFECTION - The present invention provides an isolated peptide having an amino acid residue sequence that comprises at least one human cytomegalovirus glycoprotein B (HCMV-gB) sequence segment, each HCMV-gB sequence segment consisting of at least 8 and not more than 60 consecutive amino acid residues from residues 146 to 315, residues 476 to 494 of SEQ ID NO: 1, or from a sequence variant of residues 146 to 315 or 476 to 494 of SEQ ID NO: 1 that has at least 70% sequence identity thereto. The peptides of the invention are useful for treating, preventing, or inhibiting a herpesvirus (e.g., Herpes Simplex Virus-1, Human Cytomegalovirus, and the like) infection in a subject. | 01-03-2013 |
20140045743 | COMPOSITIONS AND METHODS FOR CORONAVIRUS INHIBITION - The present invention provides compositions and methods for treating a coronavirus infection. A method embodiment comprises administering a polypeptide (preferably in a biocompatible pharmaceutical carrier) to a subject suffering from a coronavirus infection. The polypeptide comprises or consists of at least a portion of the fusion initiation region (FIR) of a coronavirus fusion protein. In some embodiments, the polypeptide comprises or consists of a sequence selected from SEQ ID NO: 2, 22, 23, 24, and 25 or an 8 to 40 contiguous amino acid residue portion thereof. | 02-13-2014 |
20140178422 | PRIMARY MESENCHYMAL STEM CELLS AS A VACCINE PLATFORM - Episomally transfected primary mesenchymal stem cells (MSC) express a polypeptide consisting of an antigenic polypeptide (e.g., one or more polypeptides) relating to a pathogen (e.g., one or more virus, bacterium, or parasite). The antigenic polypeptide can have the amino acid sequence of a natural polypeptide from the pathogen or an amino acid sequence differing from the natural sequence by one or more conservative amino acid substitutions. Uses and method for treating or preventing infections with episomally transfected primary MSC also are described. | 06-26-2014 |
20140194347 | INFLUENZA INHIBITING COMPOSITIONS AND METHODS - The present invention provides peptides, peptide analogs, peptide derivatives and pharmaceutical compositions useful for treating or preventing influenza infections or preventing the person-to-person transmission of an influenza infection. A peptide of the invention comprises an influenza virus-cell fusion inhibiting portion of the fusion initiation region (FIR) of a wild-type influenza hemagglutinin 2 protein or a variant thereof. In a preferred embodiment, a peptide of the invention consists of 8 to 40 consecutive amino acid residues a portion of a wild-type influenza hemagglutinin 2 protein or a variant thereof, the portion of the protein comprising the FIR of the protein and up to five amino acid residues on the amino-terminal and carboxy-terminal sides of the FIR. | 07-10-2014 |
20140243256 | ARENAVIRUS INHIBITING PEPTIDES AND USES THEREFOR - The present invention describes peptides which inhibit fusion of an arenavirus (e.g., Pichinde virus; PICV) with a host cell membrane. The arenavirus inhibiting (AVI) peptides described herein comprise a segment of the GP2 protein of an arenavirus. The AVI peptides are useful for inhibiting arenavirus-to-host cell membrane fusion and for treating arenavirus infections. In a particular embodiment, the arenavirus inhibiting peptide comprises a segment of PICV glycoprotein 2 (PICV GP2; SEQ ID NO: 1), Tamiami virus (TAMV) GP2 (SEQ ID NO: 14), or Lassa virus (LASV) GP2 (SEQ ID NO: 15). In particular, the segment is selected from a region of an arenavirus GP2 extending from the N-terminus into the first half of the FIR (i.e., from residues 1 through 105 of SEQ ID NO: 1, SEQ ID NO: 14, or SEQ ID NO: 15). | 08-28-2014 |
20140377740 | SOLUBLE AND MEMBRANE-ANCHORED FORMS OF LASSA VIRUS SUBUNIT PROTEINS - Soluble and membrane-anchored forms of Lassa virus (LASV) glycoprotein 1 (GP1), glycoprotein 2 (GP2), the glycoprotein precursor (GPC), the nucleocapsid protein (NP), and the nucleic acids encoding these proteins are disclosed, as well as diagnostic and preventative methods using these compositions. Also disclosed are methods including preparation of vaccines, factors (e.g. small molecules) that inhibit LASV infectivity, and diagnostic and therapeutic antibodies including neutralizing antibodies for the prevention and treatment of infection by LASV and other arenaviruses. | 12-25-2014 |